Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study

AIM: To report the final results of the 5-year follow-up of the non-randomized SafeHER Phase III study (NCT01566721) describing the safety, tolerability, and efficacy of subcutaneous (SC) trastuzumab alone and in combination with concurrent or sequential chemotherapy. METHODS: Patients with human ep...

Descripción completa

Detalles Bibliográficos
Autores principales: Gligorov, Joseph, Pivot, Xavier, Ataseven, Beyhan, De Laurentiis, Michelino, Jung, Kyung Hae, Manikhas, Alexey, Abdel Azim, Hamdy, Gupta, Kushagra, Alexandrou, Ari, Herraez-Baranda, Luis, Tosti, Nadia, Restuccia, Eleonora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249556/
https://www.ncbi.nlm.nih.gov/pubmed/35487845
http://dx.doi.org/10.1016/j.breast.2022.03.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249556/
https://www.ncbi.nlm.nih.gov/pubmed/35487845
http://dx.doi.org/10.1016/j.breast.2022.03.001

Ejemplares similares